Innovation @ Penn: Translating Discovery into Targeted Therapies

PCI is hosting our Innovation @ Penn program in San Francisco on January 12, 2026, at 3 pm. This signature event, held concurrently during the annual JP Morgan Healthcare Conference, is an excellent opportunity to learn about emerging areas of innovation and opportunities for partnership with Penn. The program attracts professionals from across the life science industry, the investor community, and other stakeholders, and provides a platform for in-depth discussions about emerging healthcare technologies and their practical applications.

PCI is honored to have an outstanding group of participants in this year's panel, including leading luminaries Peter Marks, MD, PhD, Senior Vice President of Molecule Discovery & Head of Infectious Disease at Eli Lilly, and former Director of the FDA’s Center for Biologics Evaluation and Research, Jim Wilson, MD, PhD, Emeritus Professor of Medicine (Translation of Medicine and Human Genetics) at Penn Medicine, Founder and CEO of Gemma Biotherapeutics, and Founder and Executive Chair of Franklin Biolabs, and Allison Rae Greenplate, PhD, Adjunct Assistant Professor of Systems Pharmacology and Translational Therapeutics and Director of Immune Health at Penn Medicine. Laura Shawver, PhD, former President and CEO of Capstan Therapeutics, will serve as moderator of the panel and Jonathan Epstein, MD, PhD, Dean, Perelman School of Medicine and Executive Vice President of the University of Pennsylvania for the Health System, will deliver keynote remarks.